“Four years of European research on the development of universal influenza vaccines: what have we learnt, and how can we move forward?”

The EDUFLUVAC partners, as part of their work programme on the development of a broadly reactive influenza vaccine, are planning a workshop in close collaboration with the FLUTCORE and UNISEC consortia entitled: “Four years of European research on the development of universal influenza vaccines: what have we learnt and how can we move forward?”.

The workshop will be held in Brussels, Belgium on 12-14 June 2017

World Malaria Day is a chance to shine a spotlight on the global effort to control malaria. Each year on April 25, Roll Back Malaria (RBM) partner organizations unite around a common World Malaria Day theme.

A meeting report summarising the outcome of the EDUFLUVAC workshop on “Immunoassay standardisation for universal influenza vaccines” was recently published on Influenza and Other Respiratory Viruses journal.

The development of broadly reactive influenza vaccines raises the need to identify the most appropriate immunoassays that can be used for the evaluation of so-called “universal” influenza vaccines, and to explore a path towards the standardisation of such assays.  To address this critical topic, a workshop on “Immunoassay standardisation for universal influenza vaccines” was co-organised in June 2015 by the EDUFLUVAC consortium, a European Union funded project coordinated by the European Vaccine Initiative, and the National Institutes of Health / National Institute of Allergy and Infectious Diseases, USA. 

The workshop agenda encompassed a wide range of immunoassays that can be used to assess immune responses to broadly reactive influenza vaccines, from classical serological assays to assays measuring cell mediated immunity.  The workshop audience agreed that it was not possible to establish one universal immunoassay for universal influenza vaccine(s) because the approaches towards these vaccines differ significantly in their nature and immunogenicity properties.  Therefore, different scientific rationales for the choice of the immunoassay selection are required for the development of different universal influenza vaccines.  The meeting agreed that standardisation of the immunoassays is an important goal but that there is a long way to go.  A clear need for more collaboration on harmonisation of immunoassays was identified and the European - American partnership established during the organisation of this workshop was recognised as a clear asset in this direction and will be sustained.

EVI extends a warm welcome to María del Mar Castro. Ms del Mar Castro joins EVI with a fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO). She began her one-year Clinical Research and Development fellowship on 09 January 2017. 

The article “Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants” was published by Carly Bliss et al. in Molecular Therapy.


A call for free services is running by EURIPRED. EURIPRED facilitates and supports translational research for poverty related diseases, such as HIV, TB, malaria and hepatitis.

The free services are: • Access to biological materials and reference reagents/standards facilitated by the National Institute of Biological Standards and Control (NIBSC), UK; • Access to microarray facility for screening & evaluation facilitated by JPT Peptide Technologies, Germany.

Applications will be assessed within about three weeks on receipt.

A new paper related to the MVVC project has recently been published in the PLoS One journal.

EVI has expanded its portfolio in a new disease of poverty through the recently initiated ZIKAVAX project.

The following influenza reagents are now available on the NIBSC website:

Influenza Virus Infectious X-283A 42420 ExE1

Influenza Virus Infectious X-285A 42440 ExE1

Influenza Virus Infectious X-285 42430 ExE1